FAM177A1 Research Fund

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2022

Legal Domicile

Principal Officer

Jill Hawkins

Phone

2063105575

Tax Period

2025-01-01 to 2025-12-31

FAM177A1 Research Fund, founded in 2022, is a small nonprofit in the Medical Research sector that reported $334K in total revenue in fiscal year 2025. Revenue grew 9% year-over-year, indicating healthy expansion. The organization ran a surplus of $62K, a strong 18% operating margin.

Mission

The FAM177A1 Research Fund is a family-led patient advocacy organization dedicated to improving the lives of everyone impacted by FAM177A1 Disorder. We provide hope to affected families while focusing the global research community on FAM177A1 to develop life-transformative treatm

Program Service Accomplishments

Program 1

Expenses: $153,211

Patient Advocacy & Data: Global Networking: Successfully connected with more families globally, including new cases in the Middle East and Europe, increasing the known patient cohort to facilitate...

Patient Advocacy & Data: Global Networking: Successfully connected with more families globally, including new cases in the Middle East and Europe, increasing the known patient cohort to facilitate research.

Program 2

Expenses: $93,601

Breakthrough Research & Grants: The Fund strategically allocated resources to multiple international research projects aimed at understanding the genes function and developing therapies: Gene Therapy Initiative: Funded a pioneering AAV9-based gene therapy project at Hebrew University led by Professor Rami I. Aqeilan, aiming to deliver functional copies of the FAM177A1 gene. CURE Epilepsy Partnership: Formed a significant partnership with CURE Epilepsy to co-fund a $100,000 grant. This project, led by Dr. Berrak Ugur at Yale University, utilizes patient-derived organoids (brain-in-a-dish) to study how FAM177A1 loss affects neuronal growth and protein transport in the Golgi complex. Model Organism Development: Continued funding for research at the University of Portsmouth (UK) using Xenopus (frog) models to test potential treatments and study early brain development mysteries. Drug Repurposing: Advanced work on fruit fly models to identify existing medications that might be effective for FAM177A1 patients.

Program 3

Fundraising & Awareness: The Organization saw a record-breaking year for community engagement: FAM JAM 2025: The 2nd annual FAM JAM event in Seattle raised $280,000, directly fueling the research...

Fundraising & Awareness: The Organization saw a record-breaking year for community engagement: FAM JAM 2025: The 2nd annual FAM JAM event in Seattle raised $280,000, directly fueling the research pipeline. Impact Reporting: Released the 2024 Impact Report in March 2025, providing transparency and documenting the foundations growth and scientific strategy for donors.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2025)

Revenue Breakdown

Contributions & Grants $362,115

Program Service Revenue $0

Investment Income $4,967

Other Revenue $-33,251

TOTAL REVENUE $333,831

Expense Breakdown

Grants Paid $243,153

Salaries & Benefits $0

Fundraising Expenses $22,723

Program Expenses $246,812

Other Expenses $29,071

TOTAL EXPENSES $272,224

Year-over-Year Comparison

	2025	2024	Change
Revenue	$333,831	$306,239	+0.1%
Expenses	$272,224	$81,485	+2.3%
Net Income	$61,607	$224,754	-0.7%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Jill Hawkins	Founder & President	25.00	Officer Director	$0	$0	$0
Doug Hawkins	Vice President	1.00	Officer Director	$0	$0	$0
Beth Sampson	Treasurer	1.00	Director	$0	$0	$0
Michelle Bice	Secretary	1.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$333,831	$272,224	$327,249	$61,607
2024	$306,239	$81,485	$265,642	$224,754